Lifeboat Foundation

Early Bird ends TOMORROW!

Have you got your tickets yet? If not, then you just have a few hours to do so and save €200. Early Bird ends tomorrow 11:59 pm CET (15:00pm Pacific).

Accelerating rejuvenation therapies to repair the damage of aging.

Continue reading “Undoing Aging 2020” »

Hype or hyper-exciting? Kate Batz of Longevity. Capital shares her views on the Longevity landscape and its investment potential: pragmatic optimism, but full of opportunity.

Should we be forced to die? Live? We’re going to dig into some deep questions about health and longevity in our discussion this week with the CEO of BioViva Sciences, Elizabeth Parrish. BioViva is dedicated to improving healthy human longevity through bioinformatics used in health predictions and recommendations, precision medicine, and the discovery of novel biomarkers by applying state of the art computational methods on vast collections of biological data.

DARPA has established a new partnership with U.S. industry to jointly develop and deploy advanced robotic capabilities in space. The agency has signed an Other Transactions for Prototypes agreement with Space Logistics, LLC, a wholly-owned subsidiary of Northrop Grumman Corporation, as its commercial partner for the Robotic Servicing of Geosynchronous Satellites (RSGS) program.

The RSGS program’s objective is to create a dexterous robotic operational capability in geosynchronous orbit that can extend satellite life spans, enhance resilience, and improve reliability for current U.S. space infrastructure. The first step is the RSGS program’s development of a dexterous robotic servicer, which a commercial enterprise will then operate.

“DARPA remains committed to a commercial partnership for the execution of the RSGS mission,” said Dr. Michael Leahy, director of DARPA’s Tactical Technology Office. “Building upon the successes of the DARPA Orbital Express mission and the recent successful docking of Space Logistics’ Mission Extension Vehicle-1, the agency seeks to bring dexterous on-orbit servicing to spacecraft in geosynchronous orbit (GEO), and to establish that inspection, repair, life extension, and improvement of our valuable GEO assets can be made possible and even routine.”

Ogba Educational Clinic

EXCLUSIVE: In a plot which seems straight out of the Netflix original series Altered Carbon, experts have told Daily Star Online the wealthy could soon achieve immortality.

One of the hallmarks of cancer is cell immortality. A Northwestern University organic chemist and his team now have developed a promising molecular tool that targets and inhibits one of cell immortality’s underlying gears: the enzyme telomerase.

This enzyme is found overexpressed in approximately 90% of human cancer cells and has become an important subject of study for cancer researchers. Normal cells have the gene for telomerase, but it typically is not expressed.

“Telomerase is the primary enzyme that allows cancer cells to live forever,” said Karl A. Scheidt, who led the research. “We want to short-circuit this immortality. Now we have designed a first-of-its-kind small molecule that irreversibly binds to telomerase, shutting down its activity. This mechanism offers a new pathway for treating cancer and understanding cellular aging.”

The writer is the author of “Extra Time: Ten Lessons for an Ageing World”

Is the rash of US presidential candidates aged over 70 a sign of weakness or strength? We hear that Bernie Sanders isn’t too left; he’s too old. Michael Bloomberg was alive when Harry Truman was in the White House. Joe Biden is surely as worn out as his shoe leather.

In reality, all of these characters seem in remarkably good shape. Despite being the oldest president ever to be sworn in (he was 69), Donald Trump still acts like a kid.

Researchers report an advance in the development of a blood test that could help detect pathological Alzheimer’s disease in people who are showing signs of dementia. This approach could be less invasive and less costly than current brain imaging and spinal fluid tests. The blood test detects the abnormal accumulation of a form of tau protein known as phosphorylated-tau-181 (ptau181), which is a biomarker that suggests brain changes from Alzheimer’s. The study, funded by the National Institutes of Health, was published on March 2 in Nature Medicine.

Over the past 15 years, research advances in the development of biomarkers like tau protein have enabled investigators to more accurately diagnose Alzheimer’s disease, select research participants, and measure response to investigational therapies. Tau and other biomarkers can be detected with PET scans of the brain and lab tests of spinal fluid. However, PET imaging is expensive and involves radioactive agents, and spinal fluid tests require spinal taps, which are invasive, complex and time-consuming. Simpler biomarker tests are still needed.

“The considerable time and resources required for screening research participants with PET scans and spinal taps slow the pace of enrollment for Alzheimer’s disease treatment studies,” said Richard J. Hodes, M.D., director of NIH’s National Institute on Aging (NIA), which funded much of the study. “The development of a blood test would enable us to rapidly screen a much larger and more diverse group of volunteers who wish to enroll in studies.”

1️⃣ Genomic Instability 2️⃣ Telomere Attrition 3️⃣ Epigenetic Alterations 4️⃣ Loss of Proteostasis 5️⃣ Nutrient Sensing Goes Awry 6️⃣ Mitochondrial Dysfunction 7️⃣ Cellular Senescence 8️⃣ Stem Cell Exhaustion 9️⃣ Altered Intercellular Communication.

Explore these horsemen and the strategies being deployed to defeat this decline in Chapter 10 — The Future of #Longevity ➡️ futurefasterbook.com